Teramukai et al developed a prognostic index for advanced epithelial ovarian cancer (PIEPOC). This can help identify patients who may benefit from more aggressive or novel therapies. The authors are from Kyoto University Hospital and Jikei University in Japan.
Patient selection: Stage III or IV epithelial ovarian cancer
Parameters:
(1) age in years
(2) ECOG performance scale
(3) cell type
(4) size of residual tumor
|
Parameter |
Finding |
Points |
|
age in years |
< 70 years of age |
0 |
|
|
>= 70 years of age |
1 |
|
performance score |
0 |
0 |
|
|
1 or 2 |
1 |
|
|
3 or 4 |
2 |
|
cell type |
mucinous or clear cell |
1 |
|
|
other |
0 |
|
size of residual tumor |
< 0.1 cm (< 1 mm) |
0 |
|
|
>= 0.1 cm |
2 |
total prognostic score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• The higher the score the worse the prognosis.
|
Total Score |
Prognostic Group |
Probability of 5 Year Survival |
|
0 to 2 |
low risk |
67% |
|
3 |
intermediate risk |
43% |
|
4 to 6 |
high risk |
17% |
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
ICD-10: ,
